Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines
Catalent will continue to manufacture products for Bristol-Myers Squibb while offering other customers access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms
Reading Scientific Services Ltd (RSSL) is tripling the size of its pharmaceutical microbiology laboratory with the opening of a new, state-of-the-art facility in Wokingham. The move follows sustained market demand for the consultancy’s microbiological analysis services. It not only provides the operational space to significantly increase capacity, but also signals a commitment to the future expansion of test methods and staff levels.
Psychiatry Consortium to address unmet patient needs
Today (18th June 2019) Medicines Discovery Catapult, MQ: Transforming mental health and Alzheimer’s Research UK announce an innovative drug discovery consortium with industry, supported by the Wellcome Trust.
The Consortium will focus on the identification and validation of novel drug targets for psychiatric diseases, including the psychiatric symptoms associated with dementia.
San Diego, USA and Cambridge, UK, 12 June, 2019: Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.
Medicines Discovery Catapult and Waters partner to support UK medicines discovery with advanced technology solutions
Today [12 June], Medicines Discovery Catapult announce the launch of a strategic partnership with Waters Corporation, a world leading mass spectrometry manufacturer.
The partnership will give small and medium enterprises (SMEs) working with Medicines Discovery Catapult unprecedented access to brand-new mass spectrometry technologies which are not yet fully commercially available.
An Innovation Day focused on the future of mobility has enabled leading global automotive supplier Magna International to make important connections with researchers, start-ups and companies in and around Cambridge.
The increasing popularity of the human microbiome in biotech has become a source of scientific and investor excitement in recent years. Microbiomes, or the genes of a community of microbial cells (or microbiota) which the body is host to, have unexpected benefits and implications for overall health, from regulating the immune system, to influencing conditions such as obesity, diabetes, cancer and aging.
Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
Astex welcomes positive, new data showing breast cancer drug, Kisqali® (ribociclib), cuts risk of death by up to a third when given with hormone therapy
• Cedazuridine and decitabine, administered orally as a fixed-dose combination (ASTX727), met the primary endpoint of decitabine exposure equivalence of total 5-day dosing between oral ASTX727 and IV decitabine in the phase 3 ASCERTAIN study in MDS and CMML patients
• The study confirmed that the safety profile and clinical activity of the cedazuridine and decitabine fixed-dose combination was similar to that observed in the phase 1/2 study and similar to the expected clinical profile of decitabine IV